93 BONE DISEASE
SCHEDULE FOR ROUTINE RE-IMMUNISATION
VACCINE SCHEDULE
23-valent pneumococcal polysaccharide 12 and 24 months Haemophilus influenza tybe b conjugate 12,14 and 24 months
Varicella zoster virus Not licensed at present
Infuenza Yearly lifelong resuming ≥ 6 months post HCST
Tetanus-diphtheria toxoid 12,14 and 24 months
Inactivated polio 12,14 and 24 months
Hepatitis B 12,14 and 24 months
Hepatitis A Routine administration not recommended.
Meningococcal Routine administration not recommended
MMR ≥ 24 months if immunocompetent
97
5.5.3 BONE DISEASE
This was explored to examine any impact on bone mineral density of those patients having undergone transplant with the addition of anti-CD52 monoclonal antibody in-the-bag as opposed to the more traditional preparatory regimens employing cytotoxic agents and steroids typically with post-procedure graft-versus-host prophylaxis.63,64
98
5.6 SUMMARISING COMMENT
The details in each of the inseparable yet consecutive components are specified because they were sequentially tested and, via translational research, transferred to a standard approach as the central activity of this doctoral project. They are the major source of observations making up the study and form the audited or reference database against which, firstly, outcome is defined. Secondly they delineated the cohort that qualified to be entered into the characterisation of late effects in those managed exclusively in this centre designated for transplantation by European and American Registries – including the Centre for International Blood and Marrow Transplant Research.
99
REFERENCES
1. Lagoo AS, Gong JZ, Stenzel TT, Goodman BK, Buckley PJ, Chao NJ, et al. Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment. Arch Pathol Lab Med. 2006;130:1479-88.
2. Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath® “in-the-bag” as T-cell depletion: the Leiden experience. Bone Marrow Transplant. 2006;37:1129-34.
3 Novitzky N, Thomas V, Stubbings H, Hale G, Waldmann H. Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. Cytotherapy. 2004;6:450-6.
4 Borrill V, Schlaphoff T, du Toit E, Marx M, Wood L, Jacobs P. The use of short tandem repeat polymorphisms for monitoring chimerism following bone marrow transplantation: a short report.
Hematology. 2008;13:210-4.
5 Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L, Ghavamzadeh A, Tohidast-Acrad Z. Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant. 2007;39:431-4.
6 Ippoliti C. Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm. 1998;55:1573-80.
7 Schiller LR. Chronic diarrhea. Curr Treat Options Gastroenterol. 2005;8:259-66.
8 Rodgers C, Walsh T. Nutritional issues in adolescents after bone marrow transplant: a literature review. J Pediatr Oncol Nurs. 2008;25:254-64.
9 Sefcick A, Anderton D, Byrne JL, Teahon K, Russell NH. Naso-jejunal feeding in allogeneic bone marrow transplant recipients: results of a pilot study. Bone Marrow Transplant. 2001;28:1135-9.
10 Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant. 1989;4:247-54.
11 Bolanos-Meade J, Vogelsang GB. Acute graft-versus-host disease. Clin Adv Hematol Oncol. 2004;2:672-82.
12 Ball LM, Egeler RM. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008;41 Suppl S58-64.
100
13 Oyama Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK. Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis.
Bone Marrow Transplant. 2002;29:81-5.
14 Carreras E, Fernandez-Aviles F, Silva L, Guerrero M, Fernandez de Larrea C, Martinez C, et al.
Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant. 2010;45:1417-22.
15 Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol.
2012;87:886-9.
16 Newland A. Thrombopoietin: too much or too little. Hematology. 2012;17 Suppl 1:S166-8.
17 Jillella AP, Kallab AM, Kutlar A. Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options. Bone Marrow Transplant. 2000;26:925-7.
18 George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.
Transfusion. 2004;44:294-304.
19 Takatsuka H, Wakae T, Toda A, Itoi O, Okada M, Misawa M, et al. Association of Helicobacter pylori with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome after bone marrow transplantation. Clin Transplant. 2004;18:547-51.
20 Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996;313:579-82.
21 Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev. 2012;9:CD001895.
22 Gorczynska E, Turkiewicz D, Rybka K, Toporski J, Kalwak K, Dyla A, et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 20o5;11:797-804.
23 deVries CR, Freiha FS. Hemorrhagic cystitis: a review. J Urol. 1990;143:1-9.
24 Russo P. Urologic emergencies in the cancer patient. Semin Oncol. 2000;27:284-98.
25 Seber A, Shu XO, Defor T, Sencer S, Ramsay N. Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant. 1999;23:35-40.
101
26 Khojasteh NH, Zakerinia M, Ramzi M, Haghshenas M. A new regimen of MESNA (2-mercaptoethanesulfonate) effectively prevents cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplant recipients. Transplant Proc. 2000;32:596.
27 Rosenzweig MQ, Schaefer PM, Rosenfeld CS. Prevention of transplant-related hemorrhagic cystitis using bladder irrigation with sorbitol. Bone Marrow Transplant. 1994;14:491-2.
28 Oztoprak N, Piskin N, Aydemir H, Celebi G, Akduman D, Keskin AS, et al. Piperacillin-tazobactam versus carbepenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Jpn J Clin Oncol. 2010;40:761-7.
29 James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
Antimicrob Agents Chemother. 1996;40:696-700.
30 De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Ranieri VM, di Perri G. Continuous infusion of amphotericin B deoxycholate: does decreased nephrotoxicity couple with time-dependent pharmacodynamics? Leuk Lymphoma. 2006;47:1964-6.
31 Pollack M, Heugel J, Xie H, Leisenring W, Storek J, Young JA, et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients.
Biol Blood Marrow Transplant. 2011;17:664-73.
32 Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipient. Blood.
2009;113:5711-9.
33 Mwanda WO, Whalen C, Remick SC. Burkitt’s lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa. East Afr Med J. 2005;82 Suppl:S133-4.
34 Wood L, Jacobs P. Haematology alphabet: R – Retroviral infections and the blood. The Specialist Forum.
2008;8(9):47-52.
35 Abayomi A, Sissolak G, Jacobs P. Biology of the immune paralysis and haemato-vascular complications seen in human immunodeficiency virus infection. Resources Cardiovasc Sci (Internet). 2008 Feb
(updated 2008; cited 2012 Nov 11). Available from:
http://web.mac.com/mimnoble/iWeb/Resouces%20in%20Cardivascular%20Science/Papers/1E6EEE3D -F01B-4898-AB8C-C43EEEDAB418.html
36 Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs.
fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-59.
102
37 Ljungman P, Cordonnier C, de Bock R, Einsele H, Engelhard D, Grundy J, et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1995;15:455-60.
38 Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, Rubin RH, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation practice guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2001:392-421.
39 Lengerke C, Ljubicic T, Meisner C, Loeffler J, Sinzger C, Einsele H, et al. Evaluation of the COBAS Amplicor HCMV monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:53-60.
40 World Health Organization (WHO). WHO’s pain ladder for adults (Internet). 2013 (updated 2013; cited 2013 Oct 10). Available from: www.who.int/cancer/palliative/painladder
41 Hatlebakk JG, Grinde Emken BE, Glazkov V, Hoff DA, Hausken T. Correct use of proton pump inhibitors for gastro-oesophageal reflux disease. Tidsskr Nor Legeforen. 2013;133:43-6.
42 Roxas MF, Talip BN, Crisostomo AC. Double-blind, randomized, placebo-controlled trial to determine the efficacy of eutectic lidocaine/prilocaine (EMLA) cream for decreasing pain during local anaesthetic infiltration for out-patient haemorrhoidectomy. Asian J Surg. 2003;26:26-30.
43 Nisar PJ, Scholefield JH. Managing haemorrhoids. BMJ. 2003;327:847-51.
44 Touzout M, Elie C, van Massenhove J, Maillard N, Buzyn A, Fakhouri F. Long-term renal function after allogeneic haematopoietic stem cell transplantation in adult patients: a single-centre study. Nephrol Dial Transplant. 2010;25:624-7.
45 Akahori M, Nakamae H, Hino M, Yamane T, Hayashi T, Ohta K, et al. Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue. Bone Marrow Transplant. 2003;31:585-90.
46 Sakata-Yanagimoto M, Kanda Y, Nakagawa M, Asano-Mori Y, Kandabashi K, Izutsu K, et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant.
2004;33:1043-7.
47 Gilliam AC. Update on graft-versus-host disease. J Invest Dermatol. 2004;123:251-7.
103
48 Heldal D, Brinch L, Evensen SA, Tjonnfjord GE, Aamodt G, Elgjo K, et al. Skin biopsies for early diagnosis and prognosis of graft-versus-host disease in recipients of allogeneic stem cells from blood or bone marrow. Bone Marrow Transplant. 2004;34:345-50.
49 Jacobs P, Hayhurst M, Banfield W, Wood L. Pulmonary function tests are not predictive of complications after marrow grafting. Proceedings of the 28th World Congress of the International Society of Hematology; 2000 Aug 26-30; Toronto, Canada. Int J Hematol. 2000;72 Suppl 1:70-1 Abstr 15660.
50 Hayhurst M, Banfield W, Wood L, Jacobs P. Complications after haematopoietic stem cell grafting are not reliably predicted by pulmonary function tests. Proceedings of the 41st Annual Congress of the Federation of South African Societies of Pathology (FSASP); 2001 Jul 1-4; Cape Town, South Africa.
51 Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28:425-34.
52 Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic stem cell transplantation. Curr Opin Hematol. 2012;19:324-35.
53 Toubert A. Immune reconstitution after allogeneic HSCT. In: Apperley J, Carreras E, Gluckman E, Masszi T, editors. The EBMT Handbook: haematopoietic stem cell transplantation. 6th ed. Genoa: Forum Service Editore; 2012. p. 234-47.
54 Storek J, Geddes M, Khan F, Huard B, Helg C, Chalandon Y, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol. 2008;30:425-37.
55 Williams KM, Gress RE. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2008;21:579-96.
56 Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients.
Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy. 2001;3:41-54.
57 Feuchtinger T, Lang P, Handgretinger R. Adenovirus infection after allogeneic stem cell transplantation.
Leuk Lymphoma. 2007;48:244-55.
58 Francisci D, Aversa F, Coricelli V, Carotti A, Canovari B, Falcinelli F, et al. Prevalence, incidence and clinical outcome of hepatitis B virus and hepatitis C virus hepatitis in patients undergoing allogeneic hematopoietic stem cell transplantation between 2001 and 2004. Haematologica. 2006;91:980-2.
104
59 Parkkali T, Käyhty H, Hovi T, Ölander RM, Roivainen M, Volin L, et al. A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2007;39:179-88.
60 Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44 Suppl 1:S1-26.
61 Machado CM. Reimmunization after bone marrow transplantation – current recommendations and perspectives. Braz J Med Biol Res. 2004;37:151-8.
62 Johnston BL, Conly J M. Immunization for bone marrow transplant recipients. Can J Infect Dis.
2002;13:353-7.
63 Cummings SR. Bone density screening: a new level of evidence? Ann Intern Med. 2005,142:217-9.
64 Kerschan-Schindl K, Mitterbauer M, Füreder W, Kudlacek S, Grampp S, Bieglmayer C, et al. Bone metabolism in patients more than five vears after bone marrow transplantation. Bone Marrow Transplant. 2004,34:491-6.